{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:01:47Z","timestamp":1793379707754,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"DOI":"10.1186\/s12944-025-02750-z","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T17:15:30Z","timestamp":1759166130000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["The burden of NAFLD (now referred to as MASLD)-related chronic liver disease and cirrhosis from 1990 to 2021 with projections to 2036: a comparative study of global China the United States and India"],"prefix":"10.1186","volume":"24","author":[{"given":"Juanjuan","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhao","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congle","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenchen","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"2750_CR1","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell EE, Wong VW-S, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397:2212\u201324.","journal-title":"Lancet"},{"key":"2750_CR2","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966\u201386.","journal-title":"Hepatology"},{"key":"2750_CR3","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7:851\u201361.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2750_CR4","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","volume":"18","author":"DQ Huang","year":"2021","unstructured":"Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18:223\u201338.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2750_CR5","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","volume":"6","author":"A Mantovani","year":"2021","unstructured":"Mantovani A, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6:903\u201313.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2750_CR6","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S2213-8587(22)00003-1","volume":"10","author":"N Stefan","year":"2022","unstructured":"Stefan N, Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol. 2022;10:284\u201396.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2750_CR7","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1002\/hep.30251","volume":"69","author":"Z Younossi","year":"2019","unstructured":"Younossi Z, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69:2672\u201382.","journal-title":"Hepatology"},{"key":"2750_CR8","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, et al. Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73\u201384.","journal-title":"Hepatology"},{"key":"2750_CR9","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/hep.32542","volume":"77","author":"PA Shah","year":"2023","unstructured":"Shah PA, Patil R, Harrison SA. NAFLD-related hepatocellular carcinoma: the growing challenge. Hepatology. 2023;77:323\u201338.","journal-title":"Hepatology"},{"key":"2750_CR10","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","volume":"19","author":"JV Lazarus","year":"2022","unstructured":"Lazarus JV, et al. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol. 2022;19:60\u201378.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2750_CR11","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S2468-1253(19)30039-1","volume":"4","author":"J Li","year":"2019","unstructured":"Li J, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999\u20132019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4:389\u201398.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2750_CR12","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.jhep.2018.06.025","volume":"69","author":"SE Mahady","year":"2018","unstructured":"Mahady SE, George J. Predicting the future burden of NAFLD and NASH. J Hepatol. 2018;69:774\u20135.","journal-title":"J Hepatol"},{"key":"2750_CR13","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1002\/hep.31150","volume":"71","author":"J Zhou","year":"2020","unstructured":"Zhou J, et al. Epidemiological features of NAFLD from 1999 to 2018 in China. Hepatology. 2020;71:1851\u201364.","journal-title":"Hepatology"},{"key":"2750_CR14","first-page":"58","volume":"66","author":"G Choudhuri","year":"2018","unstructured":"Choudhuri G, Chaudhari S, Pawar D, Roy DS. Etiological patterns, liver fibrosis stages and prescribing patterns of hepato-protective agents in Indian patients with chronic liver disease. J Assoc Physicians India. 2018;66:58\u201363.","journal-title":"J Assoc Physicians India"},{"key":"2750_CR15","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1089\/met.2021.0104","volume":"20","author":"A Duseja","year":"2022","unstructured":"Duseja A, et al. Clinicopathological profile and outcome of a large cohort of patients with nonalcoholic fatty liver disease from South Asia: interim results of the Indian consortium on nonalcoholic fatty liver disease. Metab Syndr Relat Disord. 2022;20:166\u201373.","journal-title":"Metab Syndr Relat Disord"},{"key":"2750_CR16","doi-asserted-by":"publisher","first-page":"993","DOI":"10.2174\/1381612826666200303114934","volume":"26","author":"T Arshad","year":"2020","unstructured":"Arshad T, Golabi P, Henry L, Younossi ZM. Epidemiology of non-alcoholic fatty liver disease in North America. Curr Pharm Des. 2020;26:993\u20137.","journal-title":"Curr Pharm Des"},{"key":"2750_CR17","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.cgh.2022.03.010","volume":"21","author":"MA Karim","year":"2023","unstructured":"Karim MA, et al. Clinical characteristics and outcomes of nonalcoholic fatty liver disease\u2013associated hepatocellular carcinoma in the United States. Clin Gastroenterol Hepatol. 2023;21:670\u201380.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2750_CR18","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1016\/S0140-6736(24)00476-8","volume":"403","author":"AE Schumacher","year":"2024","unstructured":"Schumacher AE, et al. Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950\u20132021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403:1989\u20132056.","journal-title":"Lancet"},{"key":"2750_CR19","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/S0140-6736(24)00367-2","volume":"403","author":"M Naghavi","year":"2024","unstructured":"Naghavi M, et al. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403:2100\u201332.","journal-title":"Lancet"},{"key":"2750_CR20","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","volume":"403","author":"AJ Ferrari","year":"2024","unstructured":"Ferrari AJ, et al. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403:2133\u201361.","journal-title":"Lancet"},{"key":"2750_CR21","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1002\/hep.32228","volume":"75","author":"JM Paik","year":"2022","unstructured":"Paik JM, et al. Global burden of NAFLD and chronic liver disease among adolescents and young adults. Hepatology. 2022;75:1204\u201317.","journal-title":"Hepatology"},{"key":"2750_CR22","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z","volume":"19","author":"HJ Kim","year":"2000","unstructured":"Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19:335\u201351.","journal-title":"Stat Med"},{"issue":"10","key":"2750_CR23","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/cac2.12197","volume":"41","author":"H Qiu","year":"2021","unstructured":"Qiu H, Cao S, Xu R. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer Commun. 2021;41(10):1037\u201348.","journal-title":"Cancer Commun"},{"key":"2750_CR24","doi-asserted-by":"crossref","unstructured":"Mohan, V. et al. Prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease: Mapping Across Different Indian Populations (MAP Study). Diabetes Therapy. 2025;16:1435-50.","DOI":"10.1007\/s13300-025-01748-1"},{"key":"2750_CR25","doi-asserted-by":"publisher","first-page":"100325","DOI":"10.1016\/j.metop.2024.100325","volume":"24","author":"S Umasankari","year":"2024","unstructured":"Umasankari S, et al. Exploring the epidemiology and awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) among health sciences students in an academic health care institute in India. Metab Open. 2024;24:100325.","journal-title":"Metab Open"},{"key":"2750_CR26","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.3233\/THC-231331","volume":"32","author":"H Yin","year":"2024","unstructured":"Yin H, Yan Z, Zhao F. Risk factors of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: systematic review and meta-analysis. Technol Health Care. 2024;32:3943\u201354.","journal-title":"Technol Health Care"},{"key":"2750_CR27","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41575-023-00846-4","volume":"21","author":"G Feng","year":"2024","unstructured":"Feng G, et al. Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2024;21:46\u201356.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2750_CR28","doi-asserted-by":"publisher","first-page":"5910","DOI":"10.3748\/wjg.v28.i41.5910","volume":"28","author":"Y-B Liu","year":"2022","unstructured":"Liu Y-B, Chen M-K. Epidemiology of liver cirrhosis and associated complications: current knowledge and future directions. World J Gastroenterol. 2022;28:5910.","journal-title":"World J Gastroenterol"},{"key":"2750_CR29","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/hep.29466","volume":"67","author":"C Estes","year":"2018","unstructured":"Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67:123\u201333.","journal-title":"Hepatology"},{"key":"2750_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11\u201320.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2750_CR31","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/hep.30702","volume":"70","author":"F Zhou","year":"2019","unstructured":"Zhou F, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: a systematic review and meta-analysis. Hepatology. 2019;70:1119\u201333.","journal-title":"Hepatology"},{"key":"2750_CR32","doi-asserted-by":"crossref","unstructured":"Alluhidan, M. et al. (eds.)\u00a0Overweight and Obesity in Saudi Arabia: Consequences and Solutions. International Development in Focus. Washington, DC: World Bank; 2022.","DOI":"10.1596\/978-1-4648-1828-8"},{"key":"2750_CR33","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","volume":"79","author":"H Devarbhavi","year":"2023","unstructured":"Devarbhavi H, et al. Global burden of liver disease: 2023 update. J Hepatol. 2023;79:516\u201337.","journal-title":"J Hepatol"},{"key":"2750_CR34","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1002\/hep.30626","volume":"70","author":"A Lonardo","year":"2019","unstructured":"Lonardo A, et al. Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps. Hepatology. 2019;70:1457\u201369.","journal-title":"Hepatology"},{"issue":"s2","key":"2750_CR35","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.32687\/0869-866X-2023-31-s2-1109-1114","volume":"31","author":"SY Gorbatov","year":"2023","unstructured":"Gorbatov SY, Aksenova E, Burkovskaya YV, Ivanov A, Gazheva A. Global demographic problem and active aging (literature review). Problems of Social Hygiene Public Health and History of Medicine. 2023;31(s2):1109\u201314.","journal-title":"Problems of Social Hygiene Public Health and History of Medicine"},{"key":"2750_CR36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41586-018-0457-8","volume":"561","author":"L Partridge","year":"2018","unstructured":"Partridge L, Deelen J, Slagboom PE. Facing up to the global challenges of ageing. Nature. 2018;561:45\u201356.","journal-title":"Nature"},{"key":"2750_CR37","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/dewb.12244","volume":"20","author":"M Kottow","year":"2020","unstructured":"Kottow M. Intergenerational healthcare inequities in developing countries. Dev World Bioeth. 2020;20:122\u20139.","journal-title":"Dev World Bioeth"},{"key":"2750_CR38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/archdischild-2019-318063","volume":"106","author":"M Shaunak","year":"2021","unstructured":"Shaunak M, et al. Non-alcoholic fatty liver disease and childhood obesity. Arch Dis Child. 2021;106:3\u20138.","journal-title":"Arch Dis Child"},{"key":"2750_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-018-1149-9","volume":"16","author":"AJ Sanyal","year":"2018","unstructured":"Sanyal AJ. Putting non-alcoholic fatty liver disease on the radar for primary care physicians: how well are we doing? BMC Med. 2018;16:1\u20133.","journal-title":"BMC Med"},{"key":"2750_CR40","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","volume":"396","author":"T Vos","year":"2020","unstructured":"Vos T, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204\u201322.","journal-title":"Lancet"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-025-02750-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-025-02750-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-025-02750-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T17:15:32Z","timestamp":1759166132000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-025-02750-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2750"],"URL":"https:\/\/doi.org\/10.1186\/s12944-025-02750-z","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"7 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the authors gave their consent to publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"298"}}